Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Pediatric Leukemia, Pediatrics
Phase III
Both
Chemotherapy - cytotoxic
6-thioguanine (6-TG), Cyclophosphamide (CPM), Cytarabine (ARA-C), Daunorubicin (Daunomycin), Dexamethasone, Dexrazoxane, Doxorubicin, Etoposide, Filgrastim (GCSF), High Dose Cytarabine (HD ARAC), High Dose Methotrexate (HD MTX), Ifosfamide (Ifex), Imatinib, Intrathecal MAH, Intrathecal Methotrexate, Leucovorin, Mercaptopurine, Mesna, Methotrexate, Pegaspargase (PEG-ASP), Prednisolone, Vincristine
Zarnegar-Lumley, Sara
International
Vanderbilt University
06-04-2019
Treatment
COGAALL1631
NCT03007147

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required diagnostic bone marrow sample has been fulfilled * For patients who have not previously enrolled on APEC14B1 prior to enrollment on AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if marrow sample unavailable) must be available to develop an MRD probe * In addition, laboratory reports detailing evidence of BCR-ABL1 fusion must be submitted for rapid central review within 72 hours of study enrollment

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: